Whitehawk Therapeutics (WHWK) Gross Margin (2021 - 2025)
Historic Gross Margin for Whitehawk Therapeutics (WHWK) over the last 5 years, with Q1 2025 value amounting to 89.36%.
- Whitehawk Therapeutics' Gross Margin rose 15400.0% to 89.36% in Q1 2025 from the same period last year, while for Sep 2025 it was 89.22%, marking a year-over-year increase of 18300.0%. This contributed to the annual value of 88.36% for FY2024, which is 1000.0% down from last year.
- Per Whitehawk Therapeutics' latest filing, its Gross Margin stood at 89.36% for Q1 2025, which was up 15400.0% from 89.09% recorded in Q4 2024.
- In the past 5 years, Whitehawk Therapeutics' Gross Margin ranged from a high of 100.0% in Q4 2021 and a low of 85.35% during Q4 2023
- In the last 5 years, Whitehawk Therapeutics' Gross Margin had a median value of 89.23% in 2024 and averaged 90.05%.
- Per our database at Business Quant, Whitehawk Therapeutics' Gross Margin plummeted by -104100bps in 2023 and then soared by 37400bps in 2024.
- Quarter analysis of 5 years shows Whitehawk Therapeutics' Gross Margin stood at 100.0% in 2021, then dropped by -4bps to 95.75% in 2022, then fell by -11bps to 85.35% in 2023, then rose by 4bps to 89.09% in 2024, then grew by 0bps to 89.36% in 2025.
- Its Gross Margin stands at 89.36% for Q1 2025, versus 89.09% for Q4 2024 and 88.85% for Q3 2024.